This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2225-2229, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria

Helen W. Boucher,1,2 Christine B. Wennersten,1 and George M. Eliopoulos1,2,*

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215,1 and Harvard Medical School, Boston, Massachusetts 021152

Received 1 February 2000/Returned for modification 18 April 2000/Accepted 2 May 2000


    ABSTRACT
Top
Abstract
Text
References

The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of <= 2 µg/ml, except two strains of JK diphtheroids for which the MIC was 4 µg/ml.


    TEXT
Top
Abstract
Text
References

Although tetracyclines remain valuable therapeutic agents for a variety of infections, resistance to this class limits their use against many important gram-positive bacterial pathogens. For example, only 33% of enterococci recovered at our hospital during 1997 to 1999 were susceptible to tetracycline. The glycylcyclines are novel tetracycline analogs that have activity against organisms resistant to older compounds of this class (5, 14). They inhibit protein synthesis on wild-type ribosomes and on TetM-protected, tetracycline-resistant ribosomes (15). These compounds also inhibit organisms with tetracycline efflux determinants (14). GAR-936, the 9-t-butylglycylamido derivative of minocycline, appears to be both better tolerated by hosts and more active against tetracycline-resistant strains than earlier glycylcyclines (14). The present study examined the in vitro activities of GAR-936 against gram-positive bacteria, including strains resistant to beta -lactams, glycopeptides, and other tetracyclines.

Routine clinical isolates collected at the Beth Israel Deaconess Medical Center were included regardless of tetracycline resistance patterns. Staphylococci and most pneumococci were recovered in 1998. Strains with unusual resistance traits, including glycopeptide-resistant or beta -lactamase-producing enterococci and beta -lactam-resistant streptococci, had been referred to our laboratory from various sources over several years (2, 4, 16). Wyeth-Ayerst Laboratories, Pearl River, N.Y., kindly provided GAR-936. Tetracycline, minocycline, and doxycycline were purchased from Sigma Chemical Company, St. Louis, Mo.

Activities of the antimicrobials were determined by agar dilution methods on Mueller-Hinton II agar (12). Media were supplemented with 5% sheep blood for testing streptococci and corynebacteria. Inocula of approximately 104 CFU were applied to the surfaces of plates and were incubated for 16 to 20 h at 35°C in air or in 5% CO2 (for Lactobacillus spp., Leuconostoc spp., Streptococcus spp., Pediococcus spp., and diphtheroids). Pneumococci were also tested by broth microdilution (12).

The results of susceptibility studies are shown in Table 1. GAR-936 was four times less active than minocycline against oxacillin-susceptible and -resistant strains of Staphylococcus aureus, according to a comparison of MICs at which 90% of the isolates tested were inhibited (MIC90s). However, isolates intermediately susceptible or resistant to the other compounds were inhibited by GAR-936 at <= 1 µg/ml. GAR-936 inhibited two strains of vancomycin-intermediate S. aureus (resistant to tetracycline and minocycline) at concentrations of 1 and 2 µg/ml.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Comparative in vitro activity of GAR-936

Against coagulase-negative staphylococci, GAR-936 was consistently 1 dilution less active than minocycline, based on the MIC50s and MIC90s. Again, however, the new compound inhibited tetracycline- and doxycycline-resistant strains at <= 2 µg/ml. The MICs of GAR-936 for staphylococci resistant to both tetracycline and minocycline were higher than those for strains susceptible to minocycline (Fig. 1).


View larger version (50K):
[in this window]
[in a new window]
  		FIG. 1.   MICs (geometric means) of GAR-936 for gram-positive cocci based on resistance (R) or susceptibility (S) to minocycline (Min) or tetracycline (Tet). Among enterococci and staphylococci, susceptible isolates were those for which MICs were <= 4 µg/ml and resistant isolates were those for which MICs were >= 16 µg/ml. Streptococci were grouped according to susceptibility criteria for pneumococci: MICs for susceptible isolates were <= 2 µg/ml, and MICs for resistant isolates were >= 8 µg/ml. Isolates intermediately susceptible to Tet and Min (i.e., enterococci or staphylococci for which MICs were 8 µg/ml and streptococci for which MICs were 4 µg/ml) were included with resistant groups.

Against streptococci other than pneumococci, the intrinsic potency of GAR-936, based on a comparison of MIC50s, was equivalent or slightly superior to that of minocycline. Median (modal) MICs for GAR-936 and minocycline were 0.06 (0.06) and 0.12 (0.12) µg/ml, respectively. However, all streptococcal isolates, including strains resistant to doxycycline or minocycline, were inhibited by GAR-936 at <= 0.25 µg/ml.

For pneumococci, the results shown in Table 1 were obtained by agar dilution. The activity of GAR-936 against 60 strains of Streptococcus pneumoniae, half of which were not susceptible to penicillin, was also evaluated by microdilution. The MIC50 and MIC90 were 0.03 and 0.06 µg/ml. These were within 1 dilution of agar dilution results. Individually, microdilution results were 2 dilutions lower than the agar dilution results for 11 strains, 1 dilution lower for 27, equivalent for 13, and 1 dilution greater for 4. For S. pneumoniae ATCC 49619, the broth microdilution result was 1 dilution lower than the agar dilution result.

Approximately one-third of enterococci were resistant to doxycycline or minocycline and 44% were resistant to tetracycline, whereas all were inhibited by GAR-936 at <= 2 µg/ml. Against 20 strains of Listeria monocytogenes, GAR-936 was equal in activity to minocycline and doxycycline, based on a comparison of MIC50s, but eight times more active than tetracycline. GAR-936 was the most active agent tested against Lactobacillus, Pediococcus, and Leuconostoc. Against Pediococcus spp., GAR-936 was up to 4 times more active than minocycline and 8 to 128 times more active against doxycycline and tetracycline, based on a comparison of MIC90s. The isolates least susceptible to the new drug were Corynebacterium jeikeium. Two isolates of this group were inhibited only at 4 µg/ml.

Figure 1 shows the mean MICs of GAR-936 for isolates classified by susceptibility to tetracycline and minocycline. The geometric mean MIC of GAR-936 for tetracycline-resistant, minocycline-resistant staphylococci (1 µg/ml) was 2.4 times higher than that against tetracycline-susceptible strains. However, only four staphylococcal isolates were represented in the former group. For streptococci and enterococci, the resistance phenotype did not consistently influence GAR-936's geometric mean MICs.

The MICs (in micrograms per milliliter) of GAR-936 for control organisms were as follows (subscript indicates number of times that the value was observed): for S. aureus ATCC 29213 (n = 18), 0.121, 0.2510, 0.55, and 1.02; for Escherichia coli ATCC 25922 (n = 18), 0.251, 0.58, and 1.09; for S. pneumoniae ATCC 49619 by agar dilution (n = 2), 0.062; and for S. pneumoniae ATCC 49619 by broth microdilution (n = 2), 0.032. All results were within quality control (QC) limits for tetracycline against S. pneumoniae ATCC 49619 and for tetracycline and minocycline against S. aureus ATCC 29213 (12). NCCLS-approved QC ranges are not available for minocycline against the pneumococcus or for doxycycline against either control strain. For E. coli ATCC 25922, 17 of 18 observations were within limits for tetracycline and within the previously utilized QC range (0.5 to 2 µg/ml) for minocycline, with the remaining data point being 1 dilution above that range. However, the QC range for this antibiotic and organism was recently revised to 0.25 to 1 µg/ml, based on new microdilution study results; 8 of 18 values which we obtained by agar dilution fell above this range.

The present study confirmed the findings of Petersen et al. (14) (who demonstrated MIC90s for staphylococci, streptococci, and enterococci that were generally <= 0.5 µg/ml) and extended the results to include more vancomycin-resistant enterococci, penicillin-resistant S. pneumoniae, and oxacillin-resistant staphylococci. Resistance to antibiotics has become an increasingly difficult problem in the management of infections with gram-positive bacteria (11). Methicillin-resistant S. aureus, coagulase-negative staphylococci, penicillin-resistant S. pneumoniae, and vancomycin-resistant enterococci all cause significant morbidity or mortality or both in U.S. hospitals (1, 3, 6, 7-11, 13). Such isolates are frequently resistant to multiple classes of antibiotics, including tetracyclines, erythromycin, chloramphenicol, beta -lactams, and trimethoprim-sulfamethoxazole (8). If studies in vivo confirm the efficacy and tolerability of GAR-936, the glycylcycline would appear to have the potential for broad therapeutic application against infections with gram-positive bacteria.


    ACKNOWLEDGMENTS

This study was supported by a grant from Wyeth-Ayerst Research, Pearl River, N.Y.


    FOOTNOTES

* Corresponding author. Mailing address: Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}caregroup.harvard.edu.


    REFERENCES
Top
Abstract
Text
References

1. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin---United States, 1989-1993. Morb. Mortal. Wkly. Rep. 42:597-599[Medline].
2. Collins, L. A., G. J. Malanoski, G. M. Eliopoulos, C. B. Wennersten, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37:598-601[Abstract/Free Full Text].
3. Edmond, M. B., J. F. Ober, J. D. Dawson, D. L. Weinbaum, and R. P. Wenzel. 1996. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin. Infect. Dis. 23:1234-1239[Medline].
4. Eliopoulos, G. M., A. Gardella, and R. C. Moellering, Jr. 1982. In vitro activity of Sch 29482 in comparison with other oral antibiotics. J. Antimicrob. Chemother. 9(Suppl. C):143-152.
5. Eliopoulos, G. M., C. B. Wennersten, G. Cole, and R. C. Moellering. 1994. In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob. Agents Chemother. 38:534-541[Abstract/Free Full Text].
6. Eliopoulos, G. M. 1997. Vancomycin-resistant enterococci. Infect. Dis. Clin. N. Am. 11:851-865[CrossRef][Medline].
7. Fridkin, S. K., J. R. Edwards, S. C. Pichette, E. R. Pryor, J. E. McGowan, Jr., F. C. Tenover, D. H. Culver, and R. P. Gaynes. 1999. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin. Infect. Dis. 28:1119-1125[Medline].
8. Gold, H. S., and R. C. Moellering, Jr. 1996. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453[Free Full Text].
9. Jensen, A. G., C. H. Wachmann, K. B. Poulsen, F. Espersen, J. Scheibel, P. Pkinhoj, and N. Frimodt-Moeller. 1999. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch. Intern. Med. 159:1437-1444[Abstract/Free Full Text].
10. Landman, D., M. Chockalingam, and J. M. Quale. 1999. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin. Infect. Dis. 28:1062-1066[Medline].
11. Moellering, R. C., Jr. 1998. Problems with antimicrobial resistance in gram-positive cocci. Clin. Infect. Dis. 26:1177-1178[Medline].
12. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Ostrowsky, B. E., L. Venkataraman, E. M. C. D'Agata, H. S. Gold, P. C. DeGirolami, and M. H. Samore. 1999. Vancomycin-resistant enterococci in intensive care units. Arch. Intern. Med. 159:1467-1472[Abstract/Free Full Text].
14. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744[Abstract/Free Full Text].
15. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38:1658-1660[Abstract/Free Full Text].
16. Rhinehart, E., N. E. Smith, C. Wennersten, E. Gorss, J. Freeman, G. M. Eliopoulos, R. C. Moellering, Jr., and D. A. Goldmann. 1990. Rapid dissemination of beta -lactamase-producing aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N. Engl. J. Med. 323:1814-1818[Medline].

Antimicrobial Agents and Chemotherapy, August 2000, p. 2225-2229, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fernandez-Roblas, R., Martin-de-Hijas, N. Z., Fernandez-Martinez, A. I., Garcia-Almeida, D., Gadea, I., Esteban, J. (2008). In Vitro Activities of Tigecycline and 10 Other Antimicrobials against Nonpigmented Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 52: 4184-4186 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Owen, J. S. (2007). Population Pharmacokinetics of Tigecycline in Healthy Volunteers. J Clin Pharmacol 47: 727-737 [Abstract] [Full Text]  
  • Nord, C. E., Sillerstrom, E., Wahlund, E. (2006). Effect of tigecycline on normal oropharyngeal and intestinal microflora.. Antimicrob. Agents Chemother. 50: 3375-3380 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Olson, M. W., Ruzin, A., Feyfant, E., Rush, T. S. III, O'Connell, J., Bradford, P. A. (2006). Functional, biophysical, and structural bases for antibacterial activity of tigecycline.. Antimicrob. Agents Chemother. 50: 2156-2166 [Abstract] [Full Text]  
  • Jones, C. H., Tuckman, M., Howe, A. Y. M., Orlowski, M., Mullen, S., Chan, K., Bradford, P. A. (2006). Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 505-510 [Abstract] [Full Text]  
  • Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., O'Connell, J. (2005). Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrob. Agents Chemother. 49: 3903-3909 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A. (2005). Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates. Antimicrob. Agents Chemother. 49: 3910-3918 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Yin, L.-Y., Lazzarini, L., Li, F., Stevens, C. M., Calhoun, J. H. (2005). Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55: 995-1002 [Abstract] [Full Text]  
  • Ruzin, A., Visalli, M. A., Keeney, D., Bradford, P. A. (2005). Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49: 1017-1022 [Abstract] [Full Text]  
  • Ruzin, A., Keeney, D., Bradford, P. A. (2005). AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii. Antimicrob. Agents Chemother. 49: 791-793 [Abstract] [Full Text]  
  • Credito, K., Lin, G., Ednie, L. M., Appelbaum, P. C. (2004). Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents. Antimicrob. Agents Chemother. 48: 4033-4036 [Abstract] [Full Text]  
  • Bauer, G., Berens, C., Projan, S. J., Hillen, W. (2004). Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53: 592-599 [Abstract] [Full Text]  
  • Kitzis, M. D., Ly, A., Goldstein, F. W. (2004). In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 366-367 [Full Text]  
  • Cercenado, E., Cercenado, S., Bouza, E. (2003). In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates. Antimicrob. Agents Chemother. 47: 2644-2645 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Lee, C.-M., Huang, W.-K., Wu, T.-L., Wan, J.-H., Yang, D., Shyr, J.-M., Chuang, Y.-C., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2152-2157 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Gomez, J. A., Bouza, E. (2003). In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52: 138-139 [Full Text]  
  • Nannini, E. C., Pai, S. R., Singh, K. V., Murray, B. E. (2003). Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model. Antimicrob. Agents Chemother. 47: 529-532 [Abstract] [Full Text]  
  • Visalli, M. A., Murphy, E., Projan, S. J., Bradford, P. A. (2003). AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47: 665-669 [Abstract] [Full Text]  
  • Lefort, A., Lafaurie, M., Massias, L., Petegnief, Y., Saleh-Mghir, A., Muller-Serieys, C., Le Guludec, D., Fantin, B. (2003). Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother. 47: 216-222 [Abstract] [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 46: 3164-3167 [Abstract] [Full Text]  
  • Betriu, C., Rodriguez-Avial, I., Sanchez, B. A., Gomez, M., Alvarez, J., Picazo, J. J. (2002). In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain. Antimicrob. Agents Chemother. 46: 892-895 [Abstract] [Full Text]  
  • Chopra, I., Roberts, M. (2001). Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiol. Mol. Biol. Rev. 65: 232-260 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»